Want to join the conversation?
$BIIB 2Q15 PR: TECFIDERA revenues were $883MM, up 7% vs. $700MM in 2Q14; TECFIDERA now the most prescribed oral MS therapy globally. Interferon revenues, including AVONEX and PLEGRIDY, were $690MM vs. $774MM in 2Q14. TYSABRI revenues were $463MM vs. $533MM in 2Q14. Revenues for FAMPYRA and FUMADERM were $34MM vs. $38MM in 2Q14.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.